Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Encequidar
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
Details : HHP and Hanmi Pharm will grant Gilead exclusive global rights to encequidar, a first-in-class P-glycoprotein inhibitor, within the field of virology.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 29, 2025
Lead Product(s) : Encequidar
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement